Investors Buy High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF)

Cardiff Oncology, Inc. (NASDAQ:CRDF) was the target of some unusual options trading on Tuesday. Traders acquired 2,705 call options on the stock. This represents an increase of approximately 288% compared to the average volume of 698 call options.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CRDF. Noble Financial started coverage on Cardiff Oncology in a research note on Monday, January 5th. They issued an “outperform” rating and a $12.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Cardiff Oncology presently has an average rating of “Moderate Buy” and an average target price of $11.13.

Institutional Trading of Cardiff Oncology

Several institutional investors have recently bought and sold shares of the business. Capital Advisors Wealth Management LLC acquired a new position in shares of Cardiff Oncology during the 4th quarter worth approximately $30,000. SG Americas Securities LLC purchased a new stake in Cardiff Oncology in the 4th quarter worth $44,000. Acorn Capital Advisors LLC raised its position in Cardiff Oncology by 39.3% during the third quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock worth $4,042,000 after acquiring an additional 553,317 shares during the period. Laurion Capital Management LP raised its position in Cardiff Oncology by 37.2% during the third quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock worth $5,080,000 after acquiring an additional 668,590 shares during the period. Finally, Raymond James Financial Inc. lifted its holdings in Cardiff Oncology by 70.1% during the third quarter. Raymond James Financial Inc. now owns 23,632 shares of the company’s stock valued at $49,000 after purchasing an additional 9,740 shares in the last quarter. 16.29% of the stock is owned by institutional investors and hedge funds.

Cardiff Oncology Stock Performance

Shares of NASDAQ CRDF opened at $2.00 on Wednesday. The company’s fifty day moving average price is $2.61 and its 200 day moving average price is $2.51. Cardiff Oncology has a 1 year low of $1.85 and a 1 year high of $4.99. The company has a market capitalization of $134.72 million, a PE ratio of -2.53 and a beta of 1.40.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. Cardiff Oncology had a negative net margin of 10,064.27% and a negative return on equity of 77.21%. The company had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.12 million. On average, equities analysts expect that Cardiff Oncology will post -0.99 EPS for the current year.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.